Hepatitis A and E: Update on prevention and epidemiology

Antwerp, Belgium, March 12-13, 2009

Thursday, March 12, 2009

Session 1: Opening and objectives
Chair: Paolo Bonanni, Steven Wiersma

  • 08.30 - 08.50
  • Welcome
  • Introduction of the participants
  • Introduction of the VHPB:  1.2Mb (.pdf) P. Van Damme
  • Objectives of the meeting:
    Hepatitis A
    • Provide a feedback of the Miami meeting : “Has the time come to control Hepatitis A globally” December 2007
    • Discuss the lessons learned for Western-Europe and WHO European region
    • Provide recent information on Hepatitis A epidemiology and prevention.
    • Discuss future initiatives and HAV related topics
    Hepatitis E
    • Give an overview of the virology of HEV
    • Review the disease and its worldwide epidemiology
    • Explain the zoonotic transmission of HEV
    • Assess HEV emergence in non-endemic/endemic countries
    • Discuss the vaccine against HEV its future
  • Review of the meeting programme
  • Pre-meeting document  1.6Mb (.pdf)

Hepatitis A

Session 2: Has the time come to control hepatitis A globally?
Chair: Paolo Bonanni, Steven Wiersma

08.50 – 09.20
Summary of major findings and conclusions of Global Hepatitis A meeting, Miami dec. 2007.   563Kb (.pdf)
Pierre Van Damme (UA Antwerpen, Belgium)

09.20 – 09.40
What are the risk factors with an impact on fatality rate in fulminant hepatitis A?  537Kb (.pdf)
Daniel Shouval (Hadassah-Hebrew University Hospital, Jerusalem, Israel)

09.40 – 09.25 Discussion

09.55 – 10.10 Coffee break

Session 3: Update on Hepatitis A epidemiology, prevention and control
Chair: Daniel Shouval, Vana Papaevangelou

3a. Epidemiology

10.10 – 10.25
Increase in Hepatitis A cases in the Czech Republic in 2008.  270Kb (.pdf)
J Cástková,(National Institute of Public Health, Prague, Czech Republic)

10.25 – 10.40
Community-wide outbreak of Hepatitis A in Latvia.   2.8Mb (.pdf)
J Perevoscikovs (Public Health Agency, Riga, Latvia)

10.40 – 10.50 Discussion

3b. Prevention

10.50 – 11.05
Long-term immunity induced by hepatitis A vaccines: an update.  264Kb (.pdf)
Koen Van Herck (UA Antwerpen, Belgium)

11.05 – 11.20
Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after Hepatitis A vaccination in high and low responder. 772Kb (.pdf)
Ursula Wiedermann (Medical University, Vienna, Austria)

11.20 – 11.30 Discussion

3c. Control

11.30 – 11.45
EVENT, a network for harmonization typing of HAV and for alerting on hepatitis A outbreaks   111Kb (.pdf)
Helene Norder (SMI , Stockholm, Sweden)

11.45 – 12.05
Global overview on the effectiveness of Hepatitis A vaccination programs Hepatitis A vaccination in high and low responder.  623Kb (.pdf)
Umid Sharapov (CDC, Atlanta, USA)

12.05 – 13.05 Lunch

Chair:Rui Marinho, John Ward

13.05 – 13.25
Update on Hepatitis A  epidemiology and prevention  in WHO European Region.  132Kb (.pdf)
David Mercer (WHO Euro region)

13.25 – 13.45
Review of the Hepatitis A WHO position paper: need for an update? 196Kb (.pdf)
Steven Wiersma (WHO)

13.45 – 14.00 Discussion on Hepatitis A lessons learned and future initiatives


Hepatitis E

Session 4: Introduction on Hepatitis E
Chair: Alessandro Zanetti, Selim Badur

14.10 – 14.40
Hepatitis E from A to Z:  Discovery and Characterization.  2.9Mb (.pdf)
Robert Purcell (National Institutes of Health, Maryland,USA)

14.40 – 14.55 Coffee break

Session 5: Virology, pathogenesis and natural history
Chair: Alessandro Zanetti, Selim Badur

14.55 – 15.15
Molecular epidemiology of hepatitis E, taxonomy, molecular biology,genotypes and subtypes.  299Kb(.pdf)
Helene Norder (SMI , Stockholm, Sweden)

15.15 – 15.35
Pathogenesis and natural history of hepatitis E. 1.1Mb (.pdf)
Krzysztof Krawczynski  (CDC, Atlanta, USA)

15.35 – 15.50 Discussion

Session 6: Zoönotic transmission of HEV
Chair: Pierre Van Damme, Francoise Roudot-Thoraval

15.50 – 16.10
Hepatitis E: a curious zoönosis.  753Kb (.pdf)
Nicole Pavio (AFSSA LERPA-ENVA-INRA, Ecole Nationale Veterinaire d’alfort, France )

16.10 – 16.30  
Distribution of hepatitis E virus in the environment. 999Kb (.pdf)
Rosina Girones (University of Barcelona, Spain)

16.30 – 16.45
Endemic HEV in Europe.
Erwin Duizer (RIVM, Bilthoven, The Netherlands)

16.45 – 17.00  Discussion

17.00               End meeting day 1

18.30               Drink at the Town hall

20.00               Dinner


Friday, March 13, 2009

Session 5 (continu): Virology, pathogenesis and natural history
Chair: Daniel Lavanchy, Hal Margolis

09.00 – 09.20
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. 1.4Mb (.pdf)
Nassim Kamar (Centre Hospitalier Universitaire, Rangueil, France)

Session 7: Hepatitis E and its emergence in (non-)endemic areas
Chair: Daniel Lavanchy, Hal Margolis

09.20 – 09.35 UK
Autochthonous hepatitis E in Southwest England.  461Kb (.pdf)
Harry R Dalton (Royal Cornwall Hospital Trust, UK)

09.35 – 09.50 The Netherlands
Non-travel related Hepatitis E virus infections in the Netherlands.  472Kb (.pdf)
Erwin DuizerRIVM, Bilthoven, The Netherlands)

09.50 – 10.05 France
Acute hepatitis E in south-west France over a 5-year period.  655Kb (.pdf)
Jean Michel Mansuy (CHU Toulouse, France)

10.05 – 10.20 Germany
Hepatitis E Virus Infection in Germany. 173Kb (.pdf)
Wolfgang Jilg (University of Regensburg, Germany)

10.20 – 10.35 Spain
Prevalence of hepatitis E virus infection in children in Northeast of Spain.   138Kb (.pdf)
Maria  Buti - presented by Rosina Girones (University of Barcelona, Spain)

10.35 – 10.50 Coffee break

Chair: Koen Van Herck, Mark Kane

10.50 – 11.05 Italy
Hepatitis E in Italy. 361Kb (.pdf)
Alessandro Zanetti (University of Milan, Italy)

11.05 – 11.20
The seroprevalence of HEV in the National Health and Nutrition Sample of the United States population.  647Kb (.pdf)
Kenrad Nelson> (John Hopkins School of Medicine, Baltimore, Maryland,USA)

11.20 – 11.40
Hepatitis E in Asian Region. 3.9Mb (.pdf)
Emily Gurley (Infectious Disease and Vaccine Sciences Program, Dhaka,Bangladesh)

11.40 – 12.00 Discussion

Session 8: Vaccine against HEV and its future
Chair: Koen Van Herck, Mark Kane

12.00 – 12.20
Safety and efficacy of a recombinant hepatitis E vaccine. 194Kb (.pdf)
Bruce Innis(GSK, Philadelphia, USA)

12.20 – 12.40
Hepatitis E vaccine: Clinical experience. 717Kb (.pdf)
Mrigendra Shrestha (institute Walter Reed/ AFRIMS Research Unit Nepal, Nepal)

12.40 – 13.00
Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. 1Mb (.pdf)
JamesWai-kuo Shih (National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen , China)

13.00 – 13.15  Discussion

13.15 – 14.45 Lunch

Session 9: Conclusions of the meeting
Chair: Johannes Hallauer, Wolfgang Jilg

14.00 – 15.00
Presentation of the VHPB meeting conclusions. 133Kb (.pdf)
D. FitzSimons

15.00 Close of the meeting